Product Information
BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.2146 per EA under NDC 70954041230. Its NADAC has been published 217 times since Jun 29, 2022.
FDA first approved this application on Nov 4, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Bisoprolol Fumarate and Hydrochlorothiazide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB
Bisoprolol Fumarate and HydrochlorothiazideStrength
2.5; 6.25 mg/1; mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954041230
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215562FDA Approved
11/4/2021
TE Code
AB
On Market Since
11/4/2021
Pharmacological Classes
Price Statistics
The NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB has been published 217 times since Jun 29, 2022, and over the history we have for it it has declined 40.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2146 per EA |
|---|---|
| All-time high | $0.3594 (Jul 13, 2022) |
| All-time low | $0.1729 (Nov 20, 2024) |
| 52-week high | $0.2146 |
| 52-week low | $0.1855 |
| Median price | $0.2237 |
| Average price | $0.2416 |
| Largest weekly change | +63.0% (Nov 22, 2023) |
| Weeks tracked | 217 |
| Tracking since | Jun 29, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB, manufactured by ANI Pharmaceuticals, Inc., is $0.2146 per EA (NDC 70954041230), effective Aug 19, 2026.
How has the price of BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB changed over time?
Over the history we have for it, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB has declined 40.3%. It has been tracked across 217 weekly CMS publications since Jun 29, 2022.
What are the highest and lowest recorded NADAC prices for BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB?
Since Jun 29, 2022, the NADAC for BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB has ranged from a low of $0.1729 (Nov 20, 2024) to a high of $0.3594 (Jul 13, 2022), with a median of $0.2237 per EA.
Are there cheaper alternatives to BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB, is $0.2138 per EA — about 0% below BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB.
Who manufactures BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB?
BISOPROLOL-HYDROCHLOROTHIAZIDE 2.5-6.25 MG TB (NDC 70954041230) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.